LGC SeraCare Seraseq ctDNA MRD Panel Mix

LGC Seracare has launched the Seraseq ctDNA MRD Panel Mix reference material designed for use in patient-derived cell-free DNA minimal residual disease next-generation sequencing assays. The product was developed by combining a diseased cell line, its SNP-matched normal cell line, and biosynthetic DNA variants of clinical utility and/or targeted therapeutics, the company noted. The reference material is offered as a purified mutation mix ready for sequencing library prep with no additional extraction or purification step, according to the company.